Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    34.657,35
    +318,03 (+0,93%)
     

  • Dow Jones

    39.512,84
    +125,08 (+0,32%)
     

  • Nasdaq

    16.340,87
    -5,40 (-0,03%)
     

  • Nikkei 225

    38.229,11
    +155,13 (+0,41%)
     

  • Petrolio

    78,20
    -1,06 (-1,34%)
     

  • Bitcoin EUR

    56.365,23
    -1.911,54 (-3,28%)
     

  • CMC Crypto 200

    1.261,37
    -96,64 (-7,12%)
     

  • Oro

    2.366,90
    +26,60 (+1,14%)
     

  • EUR/USD

    1,0772
    -0,0012 (-0,11%)
     

  • S&P 500

    5.222,68
    +8,60 (+0,16%)
     

  • HANG SENG

    18.963,68
    +425,87 (+2,30%)
     

  • Euro Stoxx 50

    5.085,08
    +30,67 (+0,61%)
     

  • EUR/GBP

    0,8601
    -0,0007 (-0,08%)
     

  • EUR/CHF

    0,9760
    -0,0005 (-0,05%)
     

  • EUR/CAD

    1,4718
    -0,0026 (-0,17%)
     

Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

Terns Pharmaceuticals, Inc.
·1 minuto per la lettura
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.

FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET.

A live audio webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the event.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com